181: Kinetics of engraftment following dual unrelated cord blood transplantation with reduced intensity conditioning  by Tan, P.-L. et al.
cine and ultrasound has led to the possibility of in utero diagnosis
and treatment with intrauterine transfusions. Rare cases of prema-
ture infants surviving and undergoing chronic transfusion therapy
have been reported. Hematopoietic stem cell transplant (HSCT)
has become increasingly used to cure beta thalassemia, and pro-
vides the potential to cure 0thalassemia. To date, 3 reported cases
of 0thalassemia have been treated with HSCT. Two children
underwent matched sibling HSCT at 20 and 21 months of age and
one a 5/6 HLA matched sibling umbilical cord blood transplant
(UCBT). One child had received intrauterine transfusions. We
report a case of an infant with 0thalassemia successfully treated
with intrauterine transfusions followed by unrelated donor UCBT.
The mother, of Cambodian descent, noticed decreased fetal move-
ment at 23 weeks gestation and ultrasound revealed hydrops fetalis.
Based on nationality and previous fetal loss, the suspicion of
0thalassemia was raised. UCB sampling revealed a hypochromic,
microcytic anemia with target cells. The Hgb electrophoresis dem-
onstrated Hgb Barts and Portland. Subsequent genotyping con-
ﬁrmed deletion of all 4 -globin genes. The patient received 3
intrauterine transfusions prior to delivery at 32 weeks. The hospital
course was relatively uneventful and included PRBC transfusions.
After discharge, he received 3 transfusions. Following informed
consent, at 6 months of age, he was conditioned for transplant with
busulfan, cytoan and ATG. Lacking an HLA matched sibling, he
received a 5/6 HLA matched unrelated donor UCB unit delivering
11.8  107 nucleated cells/kg. Neutrophil engraftment
(ANC500) was achieved on day  15. FK506 and methotrexate
5mg/m2 on days 1, 3 and 6 was utilized for GVHD prophylaxis.
His course was complicated by moderate venoocclusive disease,
small subdural hemorrhage, and viremia. He has not had any
evidence of graft versus host disease. Initial chimerism (STRs)
showed approximately 63% donor derived cells, since increasing
with 100% T-cell engraftment. He clinically is doing well post
transplant. This case demonstrates that intrauterine transfusion
followed by unrelated donor UCBT is feasible for the treatment of
0thalassemia.
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MPS are a group of metabolic storage diseases caused by lyso-
somal enzyme deﬁciencies resulting in the accumulation of glycos-
aminoglycans in multiple organs. Unrelated Cord Blood Trans-
plantion (UCBT) can prevent progression of organ dysfunction in
MPS. UCBT can slow or halt cognitive deterioration in early cases
of MPS II and III and improves cognitive outcome for MPS I.
However, even after full donor engraftment quality of life and
neurocognitive outcome can be adversely affected by post-trans-
plant complications such as chronic GVHD and its treatments. In
this retrospective analysis, we sought to determine how many
children receive systemic immunosuppressive (IS) drugs at the 2
year time point at the single largest center performing UCBT for
MPS. Over 90% of Duke patients with MPS are out of state and
are followed locally after 6-9 months. However, even these patients
return to Duke for yearly visits. Receiving systemic IS drugs was
chosen as a surrogate marker of active chrGvHD. Patients between
ages 1 and 50 months (median 18 months) underwent UCBT for
treatment of MPS I (Hurler), MPS II (Hunter), and MPSIII
(Sanﬁlippo Syndrome). Preparative regimen consisted of busul-
fan  cyclophosphamide with equine ATG as previously described
(COBLT study). Cyclosporine A and SoluMedrol were used as
GvHD prophylaxis. Systemic IS is expected to be tapered starting
between 6 and 12 months after UCBT. In the absence of active
GVHD, patients are weaned off all IS between 12-16 months
post-UCBT. Fourty seven (47) MPS patients were transplanted
between 1995 and September 2004, (MPSI n33, MPSII n2,
MPS IIIA n8 , MPS IIIB n4) Thirty three (33) out of the 47
were alive 2 years post-UCBT (70%). Ten out of the thirty three
survivors (30%) were receiving systemic IS drug at the 2 year visit
with the recommendation to continue. Five of these had limited
skin GvHD while ﬁve had skin plus other organ involvement
(cytopenias in 2 and GI tract in another 3). One received CellCept
only and two were on FK506 alone. Three children received 2
agents (FK506 and Prednisone). Four children received three drug
combination (FK506, low dose Prednisone, and Daclizumab).
Mean CD4 T cells were 1400/mm3  950. One patient died
before the 3 year f/up with compliactions related to GVHD, while
all other patients are alive. Taken together, a subset of MPS
patients experience prolonged exposure to IS drugs that may
hinder neurocognitive outcome after UCBT. Risk factors are cur-
rently analyzed.
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Reduced intensity conditioning (RIC) is a safer alternative to
conventional myeloablative conditioning for patients at high risk of
transplant-related morbidity/ mortality. For these patients lacking
adult donors, unrelated donor cord blood transplant (CBT) is a
feasible alternative. However, CBT with RIC may pose unaccept-
able risks of graft rejection, hence compromising outcome. To
enhance engraftment, dual donors CBTs with RIC have been
performed with promising results in pediatric patients in our cen-
tre. Little is known on the kinetics of engraftment and the deﬁning
factor/s determining the ﬁnal engrafted unit in this setting. We
analyzed these variables in 8 patients (6 with acute lymphoblastic
leukemia (ALL), 1 with hemophagolymphohistiocytosis (HLH), 1
with CD40 ligand deﬁciency) who received mismatched, dual un-
related CBT after RIC with ﬂudarabine, cyclophosphamide, low
dose TBI  low dose ATG between 2004 - 2006. All except the
patient with HLH engrafted. In 6 evaluable patients, mixed chi-
merism was noted in 50% of the patients early after transplant
(D14). Analyzed separately, all patients with ALL achieved 
90% donor chimera by D34 after transplant. All but 1 patient
with ALL (83%) are in continuous complete remission to date.
The patient with CD 40 ligand achieved complete donor chimera
on D125 after transplant. Contrary to reports of prolong mixed
chimera states after RIC, which may predispose to graft failure and
relapse, the kinetics of engraftment in our patients with ALL was
quick and robust. Early engraftment kinetics also revealed domi-
nance of one of the two units in majority of these patients.
Amongst other factors, the ﬁnal engrafted cord units have higher
post-thaw cell doses. These data demonstrated that sustained, full
donor chimera can be achieved early after RIC transplants with
dual CBT in pediatric patients with ALL without compromising
survival and relapse risks.
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Autologous stem cell transplant has failed to demonstrate beneﬁt
in most children with relapsed acute myelogenous leukemia. Ten
to twenty percent of children with acute promyelocytic leukemia
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